Barclays PLC Has $1.90 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)

Barclays PLC raised its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 124.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 175,684 shares of the technology company's stock after buying an additional 97,541 shares during the quarter. Barclays PLC owned 0.16% of Cogent Biosciences worth $1,897,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Values First Advisors Inc. acquired a new stake in shares of Cogent Biosciences during the third quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. grew its position in Cogent Biosciences by 38.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company's stock worth $43,000 after purchasing an additional 1,104 shares in the last quarter. nVerses Capital LLC acquired a new stake in Cogent Biosciences during the 3rd quarter valued at $76,000. Victory Capital Management Inc. purchased a new stake in shares of Cogent Biosciences in the third quarter valued at $113,000. Finally, Quest Partners LLC acquired a new stake in shares of Cogent Biosciences in the second quarter worth $89,000.

Analysts Set New Price Targets

Several research firms recently weighed in on COGT. Robert W. Baird upped their price target on Cogent Biosciences from $8.00 to $10.00 and gave the company a "neutral" rating in a research report on Thursday, September 5th. JPMorgan Chase & Co. increased their price target on shares of Cogent Biosciences from $19.00 to $21.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Wedbush reaffirmed a "neutral" rating and set a $11.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, November 12th. Citigroup upped their price objective on shares of Cogent Biosciences from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. Finally, Needham & Company LLC lowered shares of Cogent Biosciences from a "buy" rating to a "hold" rating in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Cogent Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $14.83.

Cogent Biosciences Price Performance

COGT traded down $0.13 during midday trading on Friday, hitting $7.74. 926,149 shares of the company's stock traded hands, compared to its average volume of 1,455,187. The company has a market cap of $854.98 million, a PE ratio of -3.12 and a beta of 1.70. Cogent Biosciences, Inc. has a one year low of $4.28 and a one year high of $12.61. The stock's fifty day simple moving average is $9.68 and its 200-day simple moving average is $9.74.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same quarter last year, the business earned ($0.64) EPS. On average, research analysts expect that Cogent Biosciences, Inc. will post -2.42 EPS for the current year.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.